BRAF(V600E) mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary Journal Article
| Authors: | Turashvili, G.; Grisham, R. N.; Chiang, S.; DeLair, D. F.; Park, K. J.; Soslow, R. A.; Murali, R. |
| Article Title: | BRAF(V600E) mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary |
| Abstract: | Aims: The most common BRAF mutation in ovarian low-grade serous neoplasms (LGSNs) involves substitution of valine by glutamic acid at position 600 (V600E). Small studies have demonstrated high specificity of immunohistochemistry with mutation-specific monoclonal antibody VE1. We sought to investigate the expression of VE1 protein in LGSNs and its correlation with BRAF mutation-associated histological features and BRAF mutation status. Methods and results: We reviewed pathology reports and available slides from ovarian serous borderline tumours (SBTs) and low-grade serous carcinomas (LGSCs) diagnosed between 2000 and 2012. VE1 immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections. Tumours with ≥50% positive cells were considered positive. Of 121 LGSNs, there were 73 SBTs, eight SBTs with micropapillary features (mpSBT) and 40 LGSCs (22 primary, 18 metastatic). VE1 was positive in 52% (38 of 73) of SBTs and 9% (two of 22) of primary LGSCs, and in none of the mpSBTs and metastatic LGSCs (P < 0.0001). Of 76 tumours with known mutation status, 42 (55%) harboured mutations, including BRAFV 600E (26, 34%), KRASG 12D (eight, 11%), and KRASG 12V (eight, 11%). BRAFV 600E mutations were present in 48% (25 of 52) of SBTs and 5% (one of 22) of LGSCs (P < 0.0001). VE1 was positive in 96% (25 of 26) of BRAFV 600E-mutated tumours and correlated with BRAF mutation-associated histological features (P < 0.0001). Conclusions: BRAFV 600E mutations are significantly more common in SBTs than in LGSCs. Immunohistochemical expression of VE1 protein is associated strongly with BRAFV 600E mutation and BRAF mutation-associated histological features. VE1 immunohistochemistry is a reliable method for the detection of BRAFV 600E mutations. © 2018 John Wiley & Sons Ltd |
| Keywords: | ovary; low-grade serous carcinoma; serous borderline tumour; ve1 immunohistochemistry; brafv 600e mutation |
| Journal Title: | Histopathology |
| Volume: | 73 |
| Issue: | 3 |
| ISSN: | 0309-0167 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2018-09-01 |
| Start Page: | 438 |
| End Page: | 443 |
| Language: | English |
| DOI: | 10.1111/his.13651 |
| PROVIDER: | scopus |
| PMCID: | PMC6105553 |
| PUBMED: | 29770477 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 4 September 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work